Navigation Links
Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
Date:6/9/2009

selective MAO inhibitors, such as phenelzine sulfate, interfere with the breakdown and elimination of tyramine in the body. Selective MAO-B inhibitors do not interfere with tyramine breakdown and elimination. Patients who take nonselective MAO inhibitors need to be cautious with the foods they eat to prevent an abnormal build-up of tyramine, which could lead to an episode of extremely high blood pressure, potentially leading to stroke or heart attack.

This study was performed as part of a Phase IV commitment to the U.S. Food and Drug Administration (FDA) at the time of AZILECT approval. The results of this study have been submitted to FDA, and Teva Neuroscience intends to work with FDA to appropriately incorporate these results into the label for AZILECT.

About the Study

The tyramine trial was a double-blind, placebo-controlled, randomized, dose-ranging study of rasagiline using a positive control (phenelzine) and a comparator drug (selegiline). In the study, 179 healthy male and female volunteers, aged 40 to 70 years, entered a run-in tyramine challenge test with escalating doses of oral tyramine from 25 mg up to 800 mg administered under fasting conditions. TSF was calculated as the tyramine dose associated with 3 consecutive increases from baseline in SBP >/=30 mm Hg over >/=10 minutes (tyramine pressor dose) in period 1 divided by the dose associated with the same change in SBP in period 3. Nonselective comparator, phenelzine, caused the highest geometric mean TSF of 17.32 +/- 12.76. Geometric mean TSF for rasagiline 1 mg once daily, the maximum approved dose, was 2.03 compared with 1.50 for pooled placebo and 2.47 for selegiline.

About AZILECT(R)

AZILECT(R) (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in the disease.

<
'/>"/>

SOURCE Teva Neuroscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
2. LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
3. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
4. Document Management Inefficiencies Cost Clinical Study Sites Time, Money
5. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
6. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
7. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
8. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
9. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
10. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Selexis ... for biologic drug discovery and mammalian cell line development, ... CHO-Mplus Libraries ™ will be presented at the 10th ... being held, September 8 – 10, 2014 at the ... , The following abstract will be presented during ...
(Date:7/30/2014)... Wellesley, MA (PRWEB) July 30, 2014 ... report, Global Markets for Enzymes in Industrial Applications ... to reach to nearly $7.1 billion by 2018, registering ... Maximum growth is estimated to be recorded in the ... the forecast period. , Enzyme technology has influenced almost ...
(Date:7/30/2014)... 2014 Researchers often use microelectronic devices ... such devices can do much more – perhaps ... researchers have looked to patterned assemblies of proteins ... engineering to characterize – and potentially control – ... envisioned to recreate animal and human physiological functions ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4
... (Amex: UPI ),a medical device company that ... dysfunctions, today reported financial,results for the third quarter of ... the third quarter of fiscal 2009 were $3.4 million ... "As we discussed in conjunction ...
... - Victhom Human Bionics Inc., "Victhom" (TSX:VHB), announced ... Mark approval for its Neurostep(TM) System, the first ... on peripheral nerves. CE Mark represents regulatory approval ... any of the Member States of the European ...
... Pharmaceutical Inc. (Nasdaq: BMRN ) announced today ... BioMarin marketing approval for Naglazyme(R) (galsulfase) for the treatment ... pleased to receive marketing approval for Naglazyme in Brazil ... VI patients in the world," said Stephen Aselage, Senior ...
Cached Biology Technology:Uroplasty Reports Third Quarter Fiscal 2009 Results 2Uroplasty Reports Third Quarter Fiscal 2009 Results 3Uroplasty Reports Third Quarter Fiscal 2009 Results 4Uroplasty Reports Third Quarter Fiscal 2009 Results 5Uroplasty Reports Third Quarter Fiscal 2009 Results 6Uroplasty Reports Third Quarter Fiscal 2009 Results 7Uroplasty Reports Third Quarter Fiscal 2009 Results 8Uroplasty Reports Third Quarter Fiscal 2009 Results 9Uroplasty Reports Third Quarter Fiscal 2009 Results 10Uroplasty Reports Third Quarter Fiscal 2009 Results 11Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3Naglazyme Approved by Brazil's National Health Surveillance Agency 2Naglazyme Approved by Brazil's National Health Surveillance Agency 3Naglazyme Approved by Brazil's National Health Surveillance Agency 4
(Date:7/30/2014)... across-the-board increase in Impact Factors for its molecular ... Reports (Thomson Reuters, 2014) show that Clinical ... in Biochemistry , Biochemical Society Transactions ... in their Impact Factors. The journals are owned ... Press Limited. , 2014 Impact Factors (2013 Impact ...
(Date:7/30/2014)... Americans make better decisions about what they eat, the ... significant changes to the Nutrition Facts label found on ... in Chemical & Engineering News (C&EN), the ... the suggested updates and the fight that has ... points out that while the Nutrition Facts label has ...
(Date:7/30/2014)... from Bjorn Brembs, professor of neurogenetics at the Institute ... figure allowing readers and reviewers to run the underlying ... important leap forward for scientific publishing, by demonstrating a ... scholarly output. , Figure 3 in fact doesn,t really ... to F1000Research , and the figure is generated ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... Chemical products, energy sources, oils, paints, and more from biomass ... thought can be obtained. Aware of this, engineer Mara Gonzlez ... as the most suitable processing techniques and technologies for refining ... organic natural resources and thus substitute them for fossil fuels ...
... This release is available in French ... resources, the National Research Council of Canada, the University ... methane-eating bacteria survive in a highly unique spring located ... Lyle Whyte, McGill University microbiologist explains that the Lost ...
... a question asked by marine scientists from the Gulf of Mexico ... and marine habitat once it has been damaged or even killed? ... may be a cheap and simple solution that can be used ... was carried out by Dr Graham Forrester, from the University of ...
Cached Biology News:Ph.D. thesis opens doors to obtaining chemical products and materials using biomass as raw material 2Ph.D. thesis opens doors to obtaining chemical products and materials using biomass as raw material 3Could life survive on Mars? Yes, expert says 2Coral transplantation the simple and cheap solution to reef restoration 2
Goat polyclonal to PINX1 ( Abpromise for all tested applications). entrezGeneID: 54984 SwissProtID: Q548A5...
... membrane-filtered isotonic and enzyme-free aqueous formulations ... agents in either Ca2+- and Mg2+-free ... Ca2+- and Mg2+-free phosphate-buffered saline for ... support substrates and each other for ...
...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml ... , 0.2 ml BLT5615 glycerol stock , 1010 ... Negative Control Lysate , 50 l S-protein HRP Conjugate ...
Biology Products: